Masimo sues US Customs over approval of Apple Watch imports

Masimo (MASI.O) has sued U.S. Customs and Border Protection (CBP) over the agency's decision to permit Apple (AAPL.O) to import Apple Watches with blood-oxygen reading technology. This move by CBP effectively reverses an earlier stance and allows Apple to reintroduce the feature, despite a U.S. International Trade Commission (ITC) import ban secured by Masimo based on patent infringement. Masimo alleges CBP's approval creates an improper loophole undermining the ITC's exclusion order, escalating the ongoing intellectual property dispute and highlighting potential challenges to the enforceability of ITC rulings.

Analysis

Masimo Corporation (MASI) has initiated new litigation, this time against U.S. Customs and Border Protection (CBP), escalating its intellectual property dispute with Apple (AAPL). The lawsuit challenges a CBP decision that permits the importation of Apple's Series 9 and Ultra 2 watches with the blood-oxygen feature re-enabled, a move that directly counters a 2023 import ban issued by the U.S. International Trade Commission (ITC) which found Apple infringed on Masimo's patents. Masimo contends that CBP's approval, reportedly granted without its consultation, creates an improper loophole that renders the ITC's exclusion order ineffective. This development is a significant positive for Apple, reflected in its positive sentiment score of 0.7, as it allows the company to restore a key product feature that was previously removed to comply with the ban. Conversely, it represents a material setback for Masimo, evident in its negative sentiment score of -0.6, as it now faces a new, complex legal battle to enforce its hard-won patent victory, introducing substantial uncertainty around its ability to protect its technology.

Key Decisions for Investors

• For Masimo (MASI) investors, this new lawsuit introduces a significant layer of legal uncertainty and headline risk, as the enforceability of its key ITC victory is now being challenged through a separate administrative channel.
• For Apple (AAPL) investors, the CBP approval is a notable de-risking event for its wearables segment, allowing the reintroduction of a key feature and mitigating the commercial impact of the ITC's prior ruling.
• Investors should closely monitor the proceedings of Masimo's lawsuit against CBP, as its outcome could set a precedent for the enforcement power of ITC exclusion orders and materially impact the competitive dynamics in the wearable technology market.